Nanotechnological approaches in the treatment of schistosomiasis: an overview

• Lucas Carvalho,
• Michelle Sarcinelli and
• Beatriz Patrício

Beilstein J. Nanotechnol. 2024, 15, 13–25, doi:10.3762/bjnano.15.2

• Technological Innovation Laboratory - Department of Physiological Sciences, Biomedical Institute, R. Frei Caneca, 94, Rio de Janeiro, Brazil 10.3762/bjnano.15.2 Abstract Schistosomiasis causes over 200,000 deaths annually. The current treatment option, praziquantel, presents limitations, including low

• ; nanoformulation; nanotechnology; neglected diseases; praziquantel; schistosoma; Introduction Schistosomiasis is a disease common in tropical countries caused by trematodes from the genus Schistosoma. More than 220 million people are affected by this disease, in addition to 800 million at risk of infection [1][2

• , gut, or bladder, depending on the species, where they elicit a marked immune response. The adult Schistosoma mansoni worms mate in the liver and lay eggs in the mesenteric venules of the intestine [4]. Nowadays, the only treatment available for this disease consists of praziquantel (PZQ) [5